# A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

> **NCT01784913** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ultimovacs ASA** · enrollment: 22 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** UV1 synthetic peptide vaccine and GM-CSF

## Key facts

- **NCT ID:** NCT01784913
- **Lead sponsor:** Ultimovacs ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-15
- **Primary completion:** 2015-07-08
- **Final completion:** 2020-10-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01784913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01784913, "A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01784913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*